FDA approval, funding, and real clinical development according to the founder of BioticsAI

Startup builders in the healthcare space can’t just quickly build and break things down. The journeys are longer, the steps are higher, and success depends on driving techniques that benefit the most from speed.

That’s exactly what Robhy Bustami, founder and CEO of BioticsAI, has been building on. His company is developing an AI ultrasound pilot that helps detect fetal abnormalities, an area where the number of undiagnosed diseases is surprisingly high. Bustami joined Isabelle Johannessen on Build Mode to discuss how the company navigated the highly regulated environment and made the team more motivated while cutting out all the red tape.

BioticsAI started out scrappy. The team created the first, working version of the device for less than $100,000, which was the most unheard of in the world for medical devices. That example helped them win the TechCrunch Startup Battle in 2023bringing original transparency and integrity. In January, they received FDA approvalwhich means that they can begin to be established in hospitals and expand the business to a new level.

From day one, the team approached product development and FDA approval. Instead of building first and identifying regulations later, they combined clinical validation, regulatory processes, and product development into one process. This means working closely with clinicians, collecting large amounts of data, and conducting regular clinical studies prior to delivery.

The FDA process itself is often seen as a black box, but Bustami emphasizes that startups shouldn’t blindly navigate it. Early discussions with the facilitators, through pre-deployment meetings, helped the team to agree on the study design and expectations. However, the danger does not end. For many investors, the big question is simple: What if the FDA says no?

In essence, long-term lists create a different kind of challenge: keeping a group stable over the years. At BioticsAI, this means building a culture of collaboration between engineers, clinicians, and researchers, ensuring that everyone sees the success that happens.

“Ensuring that everyone is fully integrated, even if they are outside of their expertise,” said Bustami, “always seeing success on the R&D side,” from clinical studies to new clinical collaborations.

Now, with FDA approval secured, BioticsAI is entering a new phase: delivery. The company is starting to roll out its technology in hospitals, with plans to expand beyond contraceptives into more healthcare settings.

Construction in health care is a long game. It takes patience, discipline, and a willingness to work with uncertainty. For startups who want to take this path, the prize isn’t just a successful company – it’s an opportunity to create something that changes the way care is delivered.

Enter Build Mode Apple Podcasts, Spotifyor wherever you like to listen. Watch all videos at YouTube. Isabelle Johannessen is our host. Build Mode created and edited by Maggie Nye. Audience Development is led by Morgan Little. And special thanks to the Foundry and Cheddar video teams.

Sign up for Battle Start: We are looking for early stage companies with an MVP. So choose an initiator (or yourself). Be sure to hear about Startup Battlefield from the Build Mode podcast. Write here.

TechCrunch Disrupt 2026: We’re back at TechCrunch Disrupt on October 13 to 15 in San Francisco, where Startup Battlefield 200 is kicking off. So if you want to impress them, or just connect with thousands of startups, VCs, and tech enthusiasts, then get your tickets.

Use code buildmode15 for 15% discount on any ticket type.